SCHEMBL474146

SCHEMBL474146

CNC(O)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.59
SIGMAR1 Q99720 4/20 0.59
SLC18A2 Q05940 1/20 0.59
TRPA1 O75762 2/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SLC6A2 P23975 2/20 0.46
MAOA P21397 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
CYP2A6 P11509 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
CYP1A2 P05177 1/20 0.45
EPHX1 P07099 1/20 0.44
CYP2D6 P10635 1/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10440174 0.83 EPHX1 (0.50) TAAR1SIGMAR1SLC18A2TRPA1NPC1
SCHEMBL16095412 0.80 TAAR1 (0.52) TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3
SCHEMBL11147449 0.80 SIGMAR1 (0.52) TAAR1SIGMAR1SLC18A2TRPA1NPC1
SCHEMBL20168603 0.80 TAAR1 (0.52) TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3
SCHEMBL3936936 0.79 CYP1A2 (0.46) TAAR1SIGMAR1SLC18A2TRPA1NPC1
SCHEMBL28127137 0.79 CYP1A2 (0.46) TAAR1SIGMAR1SLC18A2TRPA1NPC1
SCHEMBL10676875 0.78 SIGMAR1 (0.62) TAAR1SIGMAR1SLC18A2TRPA1NPC1
SCHEMBL8722485 0.78 SLC6A2 (0.53) TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4
SCHEMBL4228132 0.78 SLC6A2 (0.53) TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4
SCHEMBL19041104 0.78 ALDH1A1 (0.46) TAAR1SIGMAR1SLC18A2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107266447-A A kind of preparation method of Mirtazapine 江西永通科技股份有限公司 2017-10-20 CN claimed
EP-4181781-B1 BREATH-BASED THERAPEUTIC DRUG MONITORING METHOD UNIV KINDERSPITAL BEIDER BASEL (CH) 2026-05-20 EP disclosed
US-20230277125-A1 BREATH-BASED THERAPEUTIC DRUG MONITORING METHOD UNIVERSITÄTS-KINDERSPITAL BEIDER BASEL (CH) 2023-09-07 US disclosed
EP-3224237-A1 NECROSIS INHIBITORS National Institute Of Biological Sciences, Beijing (CN) 2017-10-04 EP disclosed
WO-2016101885-A1 NECROSIS INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-06-30 WO disclosed
EP-1348696-B1 Use of optically active clausenamides for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same INST MATERIA MEDICA CAMS (CN) 2012-02-01 EP disclosed
EP-2230312-A1 Probe compound for detecting and isolating enzymes and means and methods using the same Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2010-09-22 EP disclosed
WO-2009126635-A1 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES ABBOTT LABORATORIES (US) 2009-10-15 WO disclosed
US-6787564-B2 FOR TREATING HYPOXIA PROTECTIVE, NOOTROPIC AND NEURODEGENERATIVE DISEASES (CERBRAL ISCHEMIA, ALZHEIMER'S DISEASE, AND VASCULAR DEMENTIA) INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2004-09-07 US disclosed
WO-2004022568-A1 ARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-18 WO disclosed
US-20030207935-A1 Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES 2003-11-06 US disclosed
EP-1348696-A1 Optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2003-10-01 EP disclosed
EP-0881210-B1 Process for the production of N,N-dialkylaminophenyl alkanols CIBA SC HOLDING AG (CH) 2001-11-21 EP disclosed
US-5962739-A Process for the preparation of N,N- dialkylaminophenyl alkanols CIBA SPECIALTY CHEMICALS CORPORATION (US) 1999-10-05 US disclosed
EP-0881210-A1 Process for the production of N,N-dialkylaminophenyl alkanols Ciba SC Holding AG (CH) 1998-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207935-A1 Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use HIF1AN, HIF1A, CLN6 TAAR1 2946/4885SIGMAR1 1270/4885SLC18A2 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.